Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: FSGS Clear all
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
LIPOSORBER® LA-15
Device
Lead sponsor
Kaneka Medical America LLC
Industry
Eligibility
Up to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
10
States / cities
Loma Linda, California • Wilmington, Delaware • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced May 22, 2026, 12:30 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Kidney Disease, Glomerular Disease, Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Collapsing Glomerulopathy
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
2 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced May 22, 2026, 12:30 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid, Urologic Diseases, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases, Glomerulonephritis, Nephritis, Nephrosis
Interventions
GFB-887, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
74
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced May 22, 2026, 12:30 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Treatment Resistant Nephrotic Syndrome
Interventions
ACTHAR gel
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced May 22, 2026, 12:30 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria, Renal Tubular Toxicity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced May 22, 2026, 12:30 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Praliciguat, Placebo
Drug · Other
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
10
States / cities
Chula Vista, California • Coral Springs, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced May 22, 2026, 12:30 AM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Proteinuria
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
Up to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced May 22, 2026, 12:30 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
FG-3019
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
12 Years to 64 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
New Hyde Park, New York • Chapel Hill, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced May 22, 2026, 12:30 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
Interventions
Bardoxolone methyl capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2025 · Synced May 22, 2026, 12:30 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy, Focal Segmental Glomerulosclerosis, Glomerulopathy (Obesity-associated), Glomerulonephritis, Membranous
Interventions
Aliskiren, Valsartan
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced May 22, 2026, 12:30 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Glomerulosclerosis, Focal Segmental
Interventions
VX-147
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
33
States / cities
Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced May 22, 2026, 12:30 AM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis, Immunoglobulin A Nephropathy
Interventions
Not listed
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
San Francisco, California • Belmar, New Jersey • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced May 22, 2026, 12:30 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Kidney Diseases
Interventions
H.P. Acthar Gel
Drug
Lead sponsor
Stanford University
Other
Eligibility
16 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2014 · Synced May 22, 2026, 12:30 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Nephrotic Syndrome
Interventions
ADX-629
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
11
States / cities
Northridge, California • Aurora, Colorado • Lauderdale Lakes, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced May 22, 2026, 12:30 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome, Membranous Nephropathy, FSGS, MCD, MCD - Minimal Change Disease, Alport Syndrome
Interventions
Communication
Other
Lead sponsor
University of Michigan
Other
Eligibility
1 Year to 80 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 22, 2026, 12:30 AM EDT
Withdrawn Phase 4 Interventional
View directory record Official record
Conditions
FSGS, Renal Transplantation, Kidney Transplantation
Interventions
Acthar
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 29, 2021 · Synced May 22, 2026, 12:30 AM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
BI 764198, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
63
States / cities
Alabaster, Alabama • Huntsville, Alabama • Surprise, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 22, 2026, 12:30 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Glomerulonephritis, Nephrotic Syndrome
Interventions
Dexamethasone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced May 22, 2026, 12:30 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
GC1008
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced May 22, 2026, 12:30 AM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4
Interventions
Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg, Total Body Irradiation, ATG, Rituximab, Melphalan, CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Kidney Transplant
Drug · Radiation · Device + 1 more
Lead sponsor
Alice Bertaina
Other
Eligibility
1 Year to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2034
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2023 · Synced May 22, 2026, 12:30 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Adalimumab, Lisinopril, losartan, and atorvastatin, galactose
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
17
States / cities
Miami, Florida • Atlanta, Georgia • Kansas City, Kansas + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced May 22, 2026, 12:30 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
Plasma exchange, Cyclophosphamide
Procedure · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced May 22, 2026, 12:30 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
CCX140-B
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Torrance, California • Shreveport, Louisiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced May 22, 2026, 12:30 AM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Primary Focal Segmental Glomerulosclerosis
Interventions
Obinutuzumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced May 22, 2026, 12:30 AM EDT